The potential for crizotinib in non-small cell lung cancer: a perspective review
暂无分享,去创建一个
[1] A. Iafrate,et al. 369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) , 2010 .
[2] A. Yoshizawa,et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.
[3] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[4] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[5] F. Bassermann,et al. Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA)* , 2003, Journal of Biological Chemistry.
[6] M. Soda,et al. EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration , 2010, Clinical Cancer Research.
[7] J. Christensen,et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.
[8] Yi-long Wu,et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.
[9] G. Shapiro,et al. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.
[10] P. Jänne,et al. The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.
[11] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] M. Soda,et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma , 2011, Haematologica.
[13] C. Fletcher,et al. Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.
[14] J. Zha,et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. , 2011, Neoplasia.
[15] E. Brambilla,et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Y. Ishikawa,et al. A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.
[17] T. Shibata,et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. , 2011, Lung cancer.
[18] L. Tanoue. Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic From 1997 to 2003Yang P, Allen MS, Aubry MC, et al (Mayo Clinic, Rochester, Minn) Chest 128:452-462, 2005§ , 2007 .
[19] Ping Yang,et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. , 2009, Human pathology.
[20] S. Mori,et al. The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. , 1996, Leukemia & lymphoma.
[21] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[22] M. Werner,et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.
[23] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[24] S. Raimondi,et al. Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum , 2011, Modern Pathology.
[25] A. Gemma,et al. F1000 highlights , 2010 .
[26] D. Gandara,et al. A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue. , 2010 .
[27] R. Palmer,et al. Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.
[28] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[29] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[30] Ming Zhou,et al. Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.
[31] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[32] R. Gascoyne,et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. , 2003, Blood.
[33] H. Mano. Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer , 2008, Cancer science.
[34] H. Ji,et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Wei Zheng,et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.
[36] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[37] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[38] W. Pao,et al. EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Bustin. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.
[40] J. Downing,et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. , 2003, Blood.
[41] Y. Bang,et al. Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] A. Bernheim,et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. , 1996, Blood.
[43] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[44] A. Look,et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy , 2009, Expert review of anticancer therapy.
[45] S. Mori,et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.
[46] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[47] H. Sugimura,et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.
[48] S. Thibodeau,et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.
[49] W. Franklin,et al. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.
[50] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[51] E. Lasorsa,et al. Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth* , 2010, The Journal of Biological Chemistry.
[52] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[53] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[54] K. Pulford,et al. Anaplastic lymphoma kinase proteins in growth control and cancer , 2004, Journal of cellular physiology.
[55] F. Hirsch,et al. The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer , 2010, Clinical Cancer Research.
[56] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[57] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] C. Messa,et al. Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.
[59] Francesca Demichelis,et al. EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.
[60] K. Pulford,et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.
[61] A. Iafrate,et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Jänne,et al. Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Hyojin Kim,et al. Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[64] R. Malekzadeh,et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. , 2006, World journal of gastroenterology.
[65] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[66] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[67] P. Jänne,et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. , 2010 .
[68] M. Plummer,et al. International agency for research on cancer. , 2020, Archives of pathology.
[69] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Ping Yang,et al. Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[71] A. Ardizzoni,et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. , 2011, Lung cancer.
[72] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[73] F. Hirsch,et al. Finding ALK-positive lung cancer: what are we really looking for? , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[74] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[75] Xiong-zeng Zhu,et al. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. , 2004, Human pathology.